Rev. OFIL 2017, 27;2:187-192
Fecha de recepción: 03/05/2016 – Fecha de aceptación: 07/07/2016
Almanchel Rivadeneyra M, García Molina O, Tomás Luiz A, Muñoz Contreras MC, Menéndez Naranjo L, de la Rubia Nieto MA
Servicio de Farmacia. Hospital Clínico Universitario Virgen de la Arrixaca. Murcia (España)
Este trabajo ha sido presentado en forma de póster en el 60 Congreso Nacional de la Sociedad Española de Farmacia Hospitalaria,
celebrado en Valencia del 10 al 13 de noviembre de 2015. No ha sido publicado ni enviado para su publicación en ninguna otra revista
Miguel Almanchel Rivadeneyra
Hospital Clínico Universitario Virgen de la Arrixaca
(Servicio de Farmacia)
Ctra. Cartagena-Madrid, s/n
30120 El Palmar (Murcia)
Correo electrónico: email@example.com
Objective: To evaluate the comparative effectiveness of adalimumab (ADA) and infliximab (IFX) and the reason for stopping the treatment in patients with Crohn’s disease.
Material and methods: Retrospective, descriptive, observational study of all patients diagnosed with Crohn´s disease treated with IFX or ADA from January 2010 to December 2014. We recorded: age, sex, duration of treatment, previous therapy with other biological drugs and reason of stopping the treatment. The Kaplan-Meier method was used to measure the effectiveness of treatment, overall survival of ADA and IFX was calculated and survival was estimated at 3 years. The Log-Rank and Breslow tests were used to check whether there were differences between IFX and ADA. The Pearson Chi-Square test was used for assessing qualitative variables differences between ADA and IFX, and the Student’s t-test for quantitative variables. Data were analyzed using SPSS v.22.
Results: The study included 158 patients diagnosed with Crohn´s disease (ADA; n=81 and IFX; n=77). The mean age was 38±14 years in the ADA group and 39±13 in the IFX group (p=0.66); and 50.62% were men in the ADA group and 51.95% in the IFX group (p=0.867). The drug was received in the first line by 77.8% of patients in the ADA group and 74.4% in the IFX group. The treatment was stopped by 48.1% of patients with ADA and 51.9% with IFX. The median survival was 42.7 months with ADA [95% confidence interval (CI) 19.7-65.6%] and 36 months with IFX (95% CI 6.4-65.5%) without significant statistics difference between both drugs (Log-Rank: p=0,991; Breslow: p=0,621). Survival at 3 years was 53.1% for ADA and 49.5% for IFX (p=0.75).
Conclusions: In this study significant differences in efficiency were not found between the two anti-TNF.
Key Words: Crohn´s disease, study, comparative, effectiveness, adalimumab, infliximab.